



May 15, 2013

**The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051**

Dear Sir,

We are enclosing herewith a press release informing "Glenmark Generics receives final ANDA approvals for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg." for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

**Sanjay Kumar Chowdhary
Company Secretary & Compliance Officer**

Tel: 4018 9999 / 4018 9879

Fax No: 4018 9986 (Legal & Secretarial Dept.)

Encl: As above

Glenmark Pharmaceuticals Ltd.

Glenmark House, HDO-Corporate Building, Wing A, B D Sawant Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai 400 099
T : 91 22 4018 9999 F : 91 22 4018 9986 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026.

Glenmark Generics Ltd.



Press Release

For Immediate Release

Glenmark Generics receives final ANDA approvals for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg

May 15, 2013: Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approvals (ANDA's) from the United States Food and Drug Administration (US FDA) for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg. Glenmark will commence distribution of the product immediately.

Zolmitriptan Tablets and Zolmitriptan ODT are Glenmark's generic versions of Zomig® and Zomig ZMT® by AstraZeneca, indicated for the acute treatment of migraine headaches in adults. According to IMS Health for the 12 month period ending December 2012, the products garnered annual sales of USD 176 million.

Glenmark's current portfolio consists of 85 products authorized for distribution in the U.S. marketplace and 50 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email: corpcomm@glenmarkpharma.com